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ABSTRACT
Parker, Ashley Cox. MS. The University of Memphis. August 2011. Design and
Preliminary Investigation of Crosslinked Chitosan Sponges for Tailorable Drug Delivery
and Infection Control. Major Professor: Dr. Warren Haggard.
Musculoskeletal wound infections can be difficult to treat, often resulting in
multiple surgeries and increased costs, and can be complicated by antibiotic resistant
bacteria. The aim of this study was to use genipin, alone or with poly(nisopropylacrylamide) (PNIPAM), to crosslink chitosan sponges for a tailorable,
degradable local drug delivery system to treat known musculoskeletal pathogens.
Lyophilized uncrosslinked, genipin crosslinked, and PNIPAM/ genipin crosslinked
chitosan sponges were evaluated in vitro for degradation, antibiotic uptake, elution,
biologic activity, and biocompatibility. Crosslinked chitosan sponges exhibited
decreased degradation and increased antibiotic uptake and elution. PNIPAM/genipin
crosslinked sponges had the highest and prolonged release of antibiotics. Vancomycin
and amikacin eluted from all sponges was active against Staphylococcus aureus and
Pseudomonas aeruginosa, and did not have significant cytotoxic effects. These results
indicate that genipin crosslinked and PNIPAM/genipin crosslinked chitosan sponges have
potential as tailorable adjunctive treatments for infection control, suitable for extended
degradation and antibiotic release times.
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PREFACE
The main body of this thesis is a journal article entitled “Design and Preliminary
Investigation of Crosslinked Chitosan Sponges for Tailorable Drug Delivery and
Infection Control.” This manuscript will be submitted to the Journal of Biomedical
Materials Research Part B: Applied Biomaterials.
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CHAPTER 1:
INTRODUCTION
1.1

Statement of Clinical Problem
Wound infection and the development of osteomyelitis, a bone infection caused

by bacteria or a fungus, can be a challenging problem to treat in orthopaedics, especially
with complex musculoskeletal trauma, and can result in multiple surgeries and increased
costs.1, 2 Orthopaedic injuries comprise approximately 65% of total injuries during
military combat and osteomyelitis occurs in 2 to 15% of the patients with combat related
injuries.3 Wound infection can also be complicated by wound contamination with
antibiotic resistant bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA),
which can increase the occurrence of osteomyelitis and nosocomial infections, infections
acquired in hospitals.4 The development of a biodegradable local drug delivery system
whose drug release could be tailored depending on intended application, injury, and
antibiotic would allow for more controlled and optimized local drug delivery, providing a
more efficacious therapy for infection control.
1.2

Hypothesis
We hypothesize that in situ crosslinking of point of care antibiotic loaded chitosan

sponges will allow for tailorable and controlled drug elution, while maintaining activity
against resistant organisms, such as Staphylococcus aureus (S. aureus). The sponges will
be biocompatible and degradable, in order to eliminate a second surgery for removal of
the drug delivery system.
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CHAPTER 2:
LITERATURE REVIEW
2.1

Wound Healing
A wound can be commonly defined as a body injury that typically results in

lacerations to skin and usually contains underlying damage to other tissues. Complex
wounds typically involve multiple tissues and often do not heal quickly or even
completely.5 Comorbidities often occur and can contribute to the onset of infection and
impair wound healing.5 Long wound healing times can decrease patients’ quality of life,
physically, psychologically, and financially.5 Complex, open orthopedic wounds are
often contaminated and infection development is a serious complication.6 To understand
the issues with wound healing and how to correct these issues and improve healing time,
it is important to understand the principles of wound healing.
Wound healing involves four stages: haemostasis, inflammation, proliferation,
and remodeling. In haemostasis, platelets are activated upon injury and release chemicals
such as fibronectin to promote platelet aggregation and platelet derived growth factor
(PDGF) and transforming growth factor β (TGF-β) to mediate the wound healing
process.7 Within 24 hours of injury, inflammation begins when neutrophils are recruited
to the injury site through chemotaxis and serve as the first line of defense against
infection.7 Neutrophils remove bacteria, foreign materials, and necrotic tissue from the
wound.7 Neutrophils are eventually replaced as the predominant cell type by monocytes,
which differentiate into macrophages that also work to remove residual bacteria, foreign
material, and non-viable tissue.7 Both neutrophils and macrophages initiate the
proliferative phase by releasing various factors that recruit and activate fibroblasts and
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endothelial cells.7 The proliferation phase of wound healing begins with fibroblast
proliferation and collagen deposition in order to form a stable extracellular matrix in the
wound. 7 Granulation tissue is formed, epithelial cells construct an epithelial layer over
the wound, and endothelial cells initiate angiogenesis.7 In the remodeling phase, the
granulation tissue becomes a scar.7, 8

2.2

Wound Management
Wound management often provides faster and more comfortable wound healing,

which increases patients’ quality of life. The common steps utilized in wound
management with orthopaedic injuries and surgical sites are debridement, irrigation,
dressings, fixation, closure, and antibiotic therapy.5 All of these steps are utilized by
surgeons in order to prevent further damage to the tissues, or even amputation.
Debridement is the surgical removal of foreign debris, necrotic bone and soft
tissue from a wound, which creates a sterile healthy wound bed.5 Patients that undergo
debridement within 6 to 24 hours from injury have shown to have a decreased risk for
infection.5, 9 However, there are different opinions about the time dependence of
debridement. One study found no correlation between the time to operative debridement
to the risk of infection in patients with open high energy lower extremity trauma.10
Additionally, debridement can sometimes be logistically difficult in patients with
complex, multiple trauma.5
Irrigation is the use of a solution, usually saline, to cleanse a wound of bacteria
and traumatized tissue, and can be delivered either at low or high pressure.5 While
irrigation does decrease the bacterial load, it has been shown that in high pressure
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irrigation, the irrigation fluid can spread in a lateral direction, contributing to the
development of postoperative edema.11 Because of the consequential increase of wound
infection susceptibility, it is recommended that irrigation not be used as a preventive
measure but is reserved for contaminated wounds.11 While antibiotic solutions can be
utilized, saline is often recommended because the antibacterial solutions can create
irritation in the wound.5
Wounds are also often covered with dressings, to prevent drying of tissue, which
can cause cell death, necrosis, and infection.5, 12 Moist wound healing promotes
angiogenesis and epithelialization, thereby improving wound healing for patients.5
Some of the typical wound dressings include film dressings, foams, alginates, and even
chitosan dressings.5, 13 Some of the dressings contain silver or topical antibiotics, in order
to decrease bacterial colonization.5, 13 However, topical antimicrobials can cause
dermatitis and even facilitate Pseudomonas aeruginosa (P. aeruginosa) growth.13
Antimicrobial creams with malic acid or hypochlorite solutions do reduced bacterial
colonization; however, they can also increase inflammation of the nearby tissue.5
Both fixation and closure prevent further complications with wounds. Fixation
stabilizes the bone and allows for weight bearing, rapid bone healing, and the use of the
limb before complete healing.14 Some of the devices utilized in fixation include plates,
screws, nails, rods, and pins, depending on which area is being stabilized.5, 14 While
fixation is a critical component of healing, fixation hardware creates another surface on
which bacteria can colonize, often resulting in biofilm development.15 Closure of a
wound can decrease the risk of infection and is often conducted with skin allografts or
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muscle flaps.5 Closure with skin grafts promotes vascularization, but needs excellent
wound preparation and can have poor appearance and durability.5

2.3

Wound Infection
Although prevention of infection is the preferred route, treatment of bacterial

infections is conducted with antibiotic therapy. S. aureus is the most common organism
that causes osteomyelitis, but P. aeruginosa, Staphylococcus epidermis, Enterococcus
spp., Streptococcus spp., Mycobacterium spp, and Enterobacter spp. are also associated
with osteomyelitis, as well as numerous other wound infections.16, 17 S. aureus is a
common bacteria and is present in many places; approximately one third of the general
population is colonized with the bacteria.18 Wound healing can also be further
complicated by wound contamination with antibiotic resistant bacteria, which can
increase the risk of osteomyelitis and nosocomial infections. MRSA is a serious concern
in modern medicine and a problem in wound healing.4 MRSA is a common cause of
nosocomial infections, which compose approximately 40-70% of S. aureus infections in
hospital intensive care units.19 However, in addition to causing nosocomial infections in
patients that are already sick, MRSA also has the capability of causing aggressive
infections in children and other young and otherwise healthy people.20 According to the
Center for Disease Control and Prevention (the CDC), MRSA infections are on the rise in
hospitals; in 2005, 18,650 patients died in hospitals from MRSA infections.4
Another problem associated with wound healing in complex injuries is the
possible production of biofilms. According to an estimate by the CDC, approximately
65% of bacterial infections are associated with biofilms.21 Biofilms are adherent
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bacterial populations of single or mixed colonies with an exopolysaccharide matrix.22
Bacteria can produce biofilms on implants or other surfaces and during the adhesion
process, bacteria change their phenotypes.22 These phenotypic changes enable the
bacteria to respond to environmental conditions in varying ways, and communication
between bacterial cells can also be established.22 The communication and reactions to
environmental changes of adherent bacteria in biofilms also enables protection against
many antibacterial and antimicrobial agents.23 In biofilms, the metabolic activity of the
bacteria is reduced and the adherent bacterial cells ingest less antibiotic than planktonic
bacteria with higher metabolic activity, resulting in less susceptibility to antibiotics and
an increased minimal inhibitory concentration (MIC).23 The MIC and minimum
bactericidal concentration (MBC) can be defined as the lowest concentrations of
antibiotic or antimicrobial that inhibits growth or kills 99.9% of bacteria after an
overnight incubation, respectively.24 Researchers have found the MIC and MBC for
nonadherent P. aeruginosa to be 1 µg/ml and 50 µg/ml, respectively, but adherent P.
aeruginosa in biofilms on urinary catheters remained viable after 12 hours of exposure to
1,000 µg/ml of tobramycin.22, 25 Systemic antibiotics cannot reach such a high
concentration at a localized site without toxicity, thereby becoming ineffective against the
biofilms.23

2.4

Antibiotic Therapy
Some of the antibiotics that can be used for treating S. aureus include linezolid,

minocycline, co-trimoazole, clindamycin, tigeycline, cefazolin, oxacillin, nafcillin,
rifampicin, vancomycin, and daptomycin.26 Clindamycin, co-trimoxazole, linezolid, and
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minocycline are typically provided as treatment for skin and soft tissue infections and
necrotizing pneumonia.26 However, there can be resistance issues with clindamycin, cotrimoxazole, linezolid, and minocycline, especially in patients with health care risk
factors.26 Oxacillin, nafcillin, or cefazolin are typically given to patients without health
care risk factors while cultures are being taken.26 Tigecycline is indicated for intraabdominal infections with no clinical data involving osteomyelitis; resistance to
tigecycline has also been reported.27 Rifampcin is an option for treatment but should not
be used without another antibiotic because of the rapid development of resistant
bacteria.26 Daptomycin, a cyclic lipopeptide, has activity against Gram-positive bacteria,
including S. aureus and MRSA.27, 26 However, there is little data and experience using
daptomycin as a treatment for children under 18 years old.26 S. aureus has remained
sensitive to vancomycin overall, until the first vancomycin resistant S. aureus strains
emerged in the United States in 2002. Vancomycin is a glycopeptide that binds to the Dalanyl-D- alanine cell well precursor used in peptidoglycan crosslinking, which inhibits
cell wall synthesis.28 However, vancomycin remains the antibiotic of choice with
clinicians for MRSA, possibly until a new suitable antibiotic is found.26, 27, 29 For Gramnegative bacteria, such as Pseudomonas aeruginosa, aminoglycosides such as
gentamycin, kanamycin, tobramycin, and amikacin are often used.30 Amikacin is
commonly used to treat resistant gram-negative bacteria because amikacin has fewer
points susceptible to enzymatic attack than the other aminoglycosides.30
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2.5

Local Drug Delivery
Because systemic antibiotics cannot be administered at very high concentrations

to fight localized resistant bacteria or biofilms, local drug delivery is emerging as an
effective route for treating wounds and minimizing bacterial infections.31 In addition to
issues with antibiotic resistance, toxicity issues can arise with systemic drug delivery
because drugs are delivered to the entire body.31 The organisms that are typically
antibiotic resistant with systemic antibiotic delivery concentration levels can be
susceptible to the higher levels of antibiotics provided in local delivery.31 Additionally,
the drug can take a longer time to reach the wound when delivered systemically and some
avascular areas of the body are unreachable.31 In severe cases of infection and
osteomyelitis, the local blood supply can be compromised and antibiotics cannot be
delivered systemically to the infection site.31 In local drug delivery, ideally the wound
area is targeted and the drug therefore has less impact on other parts of the body. The
ideal local drug delivery system would be implanted, deliver the antibiotics at appropriate
levels, and then degrade so there would be no need for a second surgical procedure.31

2.6

Current Treatment Options
Several materials are currently being utilized as local drug delivery systems, but

many of these materials have disadvantages. Polymethylmethacrylate (PMMA) is one of
the most common materials used as a local drug carrier and comes in two forms:
antibiotic loaded bone cement for arthroplasties and antibiotic loaded beads for
musculoskeletal infections.2 PMMA beads have shown to reduce the infection rate in
severe open fractures from 12% to 3.7% when they were applied in combination with
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systemic drug delivery.6 Antibiotic loaded PMMA bone cement also reduced the
revision rate for patients with total hip replacements.11 The revision rate for patients
receiving only systemic antibiotics was 4.3 times greater than for patients receiving
systemic and localized drug delivery through the antibiotic loaded bone cement.32 While
PMMA has shown to be successful against bacterial infections, some major
disadvantages of the material are the need for surgical removal, possible biofilm
formation, and the development of antibiotic resistant bacteria.23 After the initial high
antibiotic release from gentamicin loaded bone cement, the long term, low concentration
of antibiotic around implants has shown the potential to develop antibiotic resistant
bacteria strains.23, 33 Antibiotic loaded bone cement has shown bacterial growth in in
vitro studies, which can easily lead to the development of biofilms on the surface.34
Another material used as a local delivery system in orthopaedic applications is
calcium sulfate. Calcium sulfate is a biocompatible, biodegradable material with
osteoconductive properties that exhibits a bolus release followed by an extended drug
release from several hours to weeks, depending on the formulation.35, 36 Because calcium
sulfate degrades over time, the need for surgical removal is eliminated and clinical
studies and animal models have shown success with minimizing infection through the use
of antibiotic loaded calcium sulfate pellets.37-39 Though calcium sulfate has been
successful at reducing infection, wounds treated with calcium sulfate can develop sterile
draining sinuses, mimicking infected draining sinuses, which many surgeons dislike.40, 41
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2.7

Chitosan
Chitosan, a positively charged linear polysaccharide produced by deacetylation of

chitin from crustacean shells, has been studied and utilized extensively in bioadhesion,
drug delivery and tissue engineering research and demonstrates promising properties for
such biomedical applications.42 Advantages of chitosan include low cost,
biodegradability, high biocompatibility, availability, and functional groups that allow for
easy chemical modification.30 The structure of chitosan is provided in Figure 1.

OH

OH

O
O

O

O
HO

HO

NH2

NH2

Fig. 1. Chemical structure of chitosan30

Chitosan has inherent antibacterial properties43, has shown to promote wound
healing44, 45 and is presently a Food and Drug Administration approved haemostatic
wound dressing utilized by the US military for the control of combat injuries.46 When
used as a drug delivery system, chitosan effectively carries antibiotics and exhibits
predictable elution rates and biodegradation.43 The development of a chitosan local drug
delivery system whose drug release could be tailored depending on intended application,
injury, and antibiotic has the potential to improve and optimize local drug delivery.
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Chitosan has been studied and successfully utilized for local drug delivery in film
form,43, 47, 48 microspheres,49, 50 and sponges.51-56 Some of the properties that have shown
or have the potential to affect the behavior of chitosan as a local drug delivery system
include degree of deacetylation, molecular weight, swelling, crosslinking, antibiotic type,
pH, drug concentration of various antibiotics, the time point at which antibiotic is loaded,
and type of chitosan.47, 48, 51, 52, 56 Additionally, combining chitosan with another polymer
or chemical modification of chitosan can alter the drug elution rate.50, 57
The antibiotic concentration loaded into the sponges can have an impact on the
release profile of the drug. In one study, chitosan and ethylcellulose sponges loaded with
a low dose of insulin (1 mg) released a higher percentage of drug content than the same
sponges loaded with a high dose of insulin (1.75 mg and 2 mg).52 However, the opposite
was true in crosslinked chitosan sponges loaded with platelet derive growth factor BB
(PDGF-BB); sponges loaded with 400 ng of PDGF-BB released more of the growth
factor than sponges loaded with 100 ng or 200 ng.53 Because the sponge material and the
type of drug typically vary in reported experiments and also influence drug elution, the
influence of antibiotic concentration on the drug release rate needs to be investigated on a
case by case basis.
The production process of the sponge, especially when the drug is loaded into the
sponge, makes a significant difference in the drug elution rate. Multiple studies have
shown chitosan sponges to exhibit slower drug release when the antibiotic was loaded
during the production of the sponge52, 56 rather than loaded post production of the
sponges. However, one of the goals of this project is to develop a chitosan sponge that is
able to be loaded with the drug at the point of care to generate an adaptable drug delivery
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system. Drug loading after the sponge is produced would allow the physicians to select
and load antibiotics immediately before implantation and would allow for more control
of the antibiotics and dosages. Therefore, the best way to create an easily adaptable
chitosan drug delivery system is through drug loading at the site of use (point of care
loading), allowing the drug to permeate and interact with the sponge, rather than the
entrapment of the drug during production of the sponges.
Molecular weight influences numerous properties of a material, including
mechanical properties and drug release. Nuthanid and co-workers determined that high
molecular weight chitosan lead to films with better mechanical properties than films with
low molecular weight chitosan, due to the increased entanglements in the higher
molecular weight chitosan.48 Additionally, in the high molecular weight chitosan, the
chitosan with a higher degree of deacetylation also lead to better mechanical properties,
most likely due to the denser packing of the additional amino groups.48
When studying either films or sponges for use in the body, both swelling and
adhesion to tissue are important properties to study. In the previously studied chitosan
films, all of the films swelled initially in phosphate buffer solution, and then decreased in
volume with time while becoming denser at the same time.48 Researchers suggest that
this decrease in volume is most likely attributed to crosslinking between the amino
groups and the phosphate, also explaining the increase in density.48 Bioadhesion is
important in wound healing because the material needs to be able to stay in place in order
to deliver the drugs to the target site. In previous research on chitosan sponges, some of
the sponges studied in an animal study did not adhere to the local tissues of goats,
reducing the effectiveness of the local drug delivery.58 Increasing the bioadhesion of the

12

chitosan sponges would allow for the sponge to stay in place and deliver the antibiotics in
a controlled manner.

2.8

Crosslinking Chitosan
Crosslinking chitosan can have a significant effect on the drug release profile of a

local delivery system. In one study, crosslinking chitosan sponges with 1.33%
glutaraldehyde reduced the drug release rate of micronized triamcinolone acetonide at pH
7.4 by over 50%.51 Crosslinking sponges composed of both chitosan and gelatin with 5%
(w/w) glutaraldehyde also reduced the release of the drug, prednisolone, when used in
acetic, formic, or lactic acid.56 Crosslinked chitosan hydrogels can be achieved through
small molecule, photo sensitive, enzymatic, and polymer polymer crosslinking.50 Some
small molecule crosslinkers that have been studied with chitosan are glutaraldehyde,
diglycidyl ether, diisocyanate, diacrylate, and genipin.50, 51, 56, 59
Chitosan hydrogels have also been successfully crosslinked through disulfide
bridges using dimethyl 3, 3 dithio bis propionimidate (DTBP) or N-acetyl-L-cysteine
(NAC) as the crosslinkers.60,61 Crosslinked chitosan hydrogel scaffolds prepared with
DTBP exhibited similar properties to glutaraldehyde crosslinked chitosan scaffolds, but
showed greater strength and less toxicity.60 The release of insulin and bovine serum
albumin could be controlled in chitosan hydrogels crosslinked with NAC by changing the
composition, loading, and disulfide bond contents.61 These NAC crosslinked chitosan
hydrogels were porous and biocompatible as well.61
Photo-cross linking offers different advantages including safety, low cost, ease of
production, and speed. A photo-sensitive chitosan hydrogel was developed by Ono and
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researchers through functionalizing chitosan with azide groups, which after ultraviolet
(UV) irradiation, are coverted into reactive nitrene groups that bind chitosan’s free amino
groups.62 This hydrogel exhibited successful controlled release of growth factors.62, 63
However, photo-cross linking can require a photosensitizer, which can create additional
toxicity issues. Riboflavin phosphate is a photosensitizer that has been researched to
crosslink collagen in rabbit and porcine eyes and has not shown immediate toxicity,
although long term side effects have not been evaluated.64 The use of the riboflavin
phosphate and UVA at 370 nm created a crosslinked collagen surface, increasing the
corneal rigidity.64 If an additional biocompatible polymer is selected, polymer-polymer
cross linking can reduce potential toxicity issues associated with small molecule and
photo cross linking. A hydrogel of chitosan and hyaluronic acid has been cross linked
through the formation of Schiff bases between the polymers and was stable for at least
four weeks and could be loaded with chondroctyes.65 Polymer polymer crosslinking has
also been studied with chitosan and oxidized dextran polysaccharides and alginate.66, 67

2.9

Genipin
Genipin is a commonly used small linker molecule for crosslinking chitosan and

is derived from geniposide by enzymatic hydrolysis with β-glucosidase.68, 69 The genipin
chemical structure is shown in Figure 2.68, 69 Geniposide is isolated from fruits from the
plant, Gardenial jasminoides Ellis, and has been used in traditional Chinese medicine.68
Extracts from the fruits are also used in a food dye known as gardenia blue, which forms
a blue pigment through the reaction of genipin with amino acids in the presence of
oxygen.69, 70
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Fig. 2. Genipin chemical structure69

Physiological studies have demonstrated that geniposide is converted to genipin in
the gastrointestinal tract in rats, with no adverse effects.69, 71 Genipin crosslinked
chitosan microspheres injected intramuscularly into the skeletal muscle of rats exhibited a
smaller inflammatory reaction and slower degradation than glutaraldehyde crosslinked
chitosan microspheres.72 In another study, researchers studied the cytotoxicity of genipin
and glutaraldehyde to 3T3 fibroblasts and found that genipin was approximately 10,000
times less cytotoxic than glutaraldehyde.73
Genipin has been used to crosslink chitosan films and microspheres for heparin
removal, protein release, and drug release.59, 68, 74, 75 Yuan and researchers evaluated the
crosslinking of chitosan microspheres with genipin for albumin release and found that as
crosslinking time and genipin concentration increased, the overall release of albumin
decreased.68 In addition to drug or protein release, crosslinking chitosan delivery systems
with genipin can change other properties. Crosslinking chitosan/poly (ethylene oxide)
blended films with genipin resulted in films with greater tensile strength, elongation at
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break, increased hydrophobicity, and slower degradation.59 Chitosan and silk fibroin
sponges have also been crosslinked with genipin for cartilage engineering, but sponges
formed from chitosan alone have not been studied with genipin.76

2.10

Poly(N-isopropylacrylamide)
Chitosan has also been studied in combination with other materials, including

gelatin,56 ethylcellulose,52 collagen and hyaluronan,54 alginate,53 and chrondroitin
sulfate,77 to form sponges for local drug delivery systems. Additional polymers are often
selected in order to complement the deficiencies of chitosan or to generate a new property
for a specific application. One such example is the preparation of “smart” hydrogels by
grafting poly(N-isopropylacrylamide) (PNIPAM) onto chitosan.57 PNIPAM is a
thermally responsive polymer, whose chemical structure is shown below in Figure 3, that
exhibits a lower critical solution temperature (LCST) and contracts when heated above its
LCST.57 An originally clear PNIPAM solution will also become opaque above its
LCST.78 As a hydrogel, PNIPAM can be a liquid at room temperature and undergo
gelation in contact with the body.57

H3C
O

CH3
NH
CH3

H3C

n

Fig. 3. Poly(N-isopropylacrylamide) chemical structure79
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Chitosan and PNIPAM have been combined to form semi-interpenetrating
networks (semi-IPNs), where one of the polymers is crosslinked, and full interpenetrating
networks (full-IPNs) where both polymers are crosslinked.80, 81 An interpenetrating
network is a blend of two polymer networks lacking covalent bonds between the two
networks and this type of polymer blend can be utilized to combine properties of different
materials.82 Differences between semi-IPNs and full-IPNS of chitosan and PNIPAM
have been found in FTIR spectra, phase transition behavior, and swelling behavior.81 A
semi-IPN of glutaraldehyde crosslinked chitosan and PNIPAM swelled faster than a fullIPN because the PNIPAM was simply embedded in the gel and the swelling behavior was
based on swelling of the chitosan.78, 81 However, in a full-IPN of formaldehyde
crosslinked chitosan and methylene bis-acryalmide crosslinked PNIPAM, there was not
as much swelling above the LCST because the chitosan swelled while the PNIPAM
contracted due to the collapse of the polymer chain.81 This stress inducing swelling
behavior could create other potential problems, such as stress cracking of the hydrogel.81
Multiple research studies with PNIPAM based hydrogels have shown minimal
cytotoxic effects on various types of cells.83-85 PNIPAM with iron oxide particles was
found to have 85-90% cell viability, as compared to approximately 97% cell viability in
cells grown directly on the polystyrene plate.83 In another study with a PNIPAM based
injectable hydrogel, researchers found that rats injected subcutaneously with the polymer
solution exhibited an initial acute wound healing phase and the tissue returned to its
normal state after 30 days.84 Polymer solutions of a synthesized, uncrosslinked PNIPAM
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and chitosan compound did not significantly inhibit the growth rate of primary cultured
corneal epithelial cells.85
In the semi-IPNs of chitosan and PNIPAM, PNIPAM is typically the polymer that
is crosslinked, either with tetraethylene glycol diacrylate (TEGDA) or methylene bisacrylamide; however, toxicity issues could arise with these small linker crosslinkers.80
Chitosan has been crosslinked when combined with PNIPAM in a semi-IPN, but it has
been crosslinked with glutaraldehyde, not genipin.86 Chitosan has also been successfully
utilized as a thermo sensitive membrane for a wound dressing in combination with
poly(urethane) and PNIPAM.87 This combination of PNIPAM with chitosan could extend
chitosan’s properties to injectable biomedical applications and generate a system that
would be pH and temperature responsive. It could also be investigated whether the
combination of PNIPAM and chitosan could create a sponge that could swell even further
when introduced into the body, possibly allowing for better bioadhesion and drug
delivery.

2.11

Conclusions
Musculoskeletal wound infections continue to be a painful, expensive, and at

times deadly medical problem, difficult to treat and further complicated by an increasing
emergence of antibiotic resistant bacteria. Debridement, irrigation, fixation, closure, and
systemic antibiotic therapy cannot stop all infections, and prevention is a key component
to minimizing infection. The delivery of antibiotics, such as vancomycin and amikacin
for the inhibition of both gram positive and negative bacteria, through degradable, local
delivery systems is ideal because of the possibility of higher antibiotic dosage, as
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compared to systemic delivery, and the elimination of an additional surgery to remove the
delivery system. The current local delivery systems have their drawbacks, including
burst release, possible biofilm formation, need for surgical removal, and the formation of
sterile draining sinuses.23, 40, 41, 88 We hypothesize that crosslinking chitosan sponges with
genipin or creating a semi-IPN of genipin crosslinked chitosan and PNIPAM will create a
more tailorable adjunctive treatment that allows for antibiotic selection and point of care
loading, sustains antibiotic elution and degradation properties, maintains activity against
Gram-positive or Gram-negative bacteria, such as S. aureus or P. aeruginosa, and
demonstrates sufficient biocompatibility. The specific aims of this research study are as
followed:
1. Create degradable genipin crosslinked and PNIPAM/ genipin crosslinked chitosan
sponges that easily absorb antibiotics in one minute of loading
2. Deliver vancomycin and amikacin from the crosslinked sponges through 72 hours
and maintain specific biologic activity against S. aureus and P. aeruginosa,
respectively
3. Ensure that neither the crosslinked sponges nor their antibiotic eluates initiate a
cytotoxic effect on cells after 24 hours of exposure
4. Evaluate the bioadhesive strength of the uncrosslinked and crosslinked chitosan
sponges
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CHAPTER 3:
Design and Preliminary Investigation of Crosslinked Chitosan Sponges for
Tailorable Drug Delivery and Infection Control

3.1

Introduction
Complex musculoskeletal wounds, both in civilian and military populations, can

be difficult to treat because they are often contaminated and infection development is a
serious complication, which may result in longer healing time, multiple surgeries, and
increased costs.1, 2, 3 Orthopaedic injuries comprise approximately 65% of total injuries
during military combat and osteomyelitis, a bone infection caused by bacteria or a
fungus, occurs in 2 to 15% of the patients with combat related injuries.4 Infection is also
especially troublesome in complex open extremity fractures from high energy trauma;
typical infection rates of civilian open fractures are 17.5-21.2%, while infection rates of
closed fractures are only 3.6-8.1%.5 Staphylococcus aureus (S. aureus) is the most
common bacterial organism that causes osteomyelitis and is very prevalent;
approximately one third of the general population is colonized with the bacteria.6 Wound
infections are also often typically polymicrobial and can be further complicated by
wound contamination with antibiotic resistant bacteria such as methicillin-resistant S.
aureus (MRSA).7 MRSA is a common cause of nosocomial infections, which compose
approximately 40-70% of S. aureus infections in hospital intensive care units.8 S. aureus
has remained sensitive to vancomycin, a glycopeptide that is often the antibiotic of choice
with clinicians for MRSA.9 For Gram-negative bacteria associated with wound
infections such as Pseudomonas aeruginosa (P. aeruginosa), amikacin, an
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aminoglycoside, is a commonly selected antibiotic due to fewer points for enzymatic
attack than other aminoglycosides.10
Local antibiotic delivery is emerging as an effective route for treating wounds and
minimizing bacterial infections because systemically delivered antibiotics cannot be
administered at very high concentrations to fight localized resistant bacteria or biofilms.11
The higher levels of antibiotics provided in local delivery, as compared to systemic
delivery, may kill bacteria before antibiotic resistance develops.11 In addition to issues
with antibiotic resistance, toxicity issues can arise with systemic drug delivery because
drugs are delivered to the entire body.12 In severe cases of infection and osteomyelitis,
the local blood supply is compromised to the extent that antibiotics cannot be delivered
systemically.13 In local drug delivery, the local wound area is targeted and thus drugs are
more effective and have less impact on other parts of the body. Polymethylmethacrylate
(PMMA) and calcium sulfate are two common local drug delivery systems, but both
materials have disadvantages. PMMA sometimes needs to be surgically removed and
there is also potential for biofilm formation and antibiotic resistant bacteria
development.1, 12 Wound treated with calcium sulfate may develop sterile draining
sinuses, mimicking infected draining sinuses, which many surgeons disfavor.14-17
Chitosan, a positively charged linear polysaccharide produced by deacetylation of
chitin from crustacean shells, is a low cost, biodegradable, and biocompatible material
that has shown success in local drug delivery systems. 18 When used as a drug delivery
system, chitosan effectively carries antibiotics and exhibits predictable elution rates and
biodegradation.19 In a lyophilized sponge delivery system, chitosan has shown to
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predictably release antibiotics and effectively inhibit the growth of S. aureus and P.
aeruginosa.20
Crosslinking chitosan can have a significant effect on the drug release profile of a
local delivery system. In one study, crosslinking chitosan sponges with 1.33%
glutaraldehyde reduced the drug release rate of micronized triamcinolone acetonide at pH
7.4 by over 50%.21 Genipin is another commonly used small linker molecule for
crosslinking chitosan and has been shown to be 10,000 times less cytotoxic on 3T3
fibroblasts than glutaraldehyde. 22 Genipin has been used to crosslink chitosan films and
microspheres for heparin removal, protein release, and drug release.23-27 Chitosan and
silk fibroin sponges have also been crosslinked with genipin for cartilage engineering, but
sponges formed from chitosan alone have not been studied with genipin.28
Chitosan and poly(N-isopropylacrylamide) (PNIPAM), a thermally responsive
polymer, have also been combined to form semi-interpenetrating networks (semi-IPNs),
where one of the polymers is crosslinked, and full interpenetrating networks (full-IPNs)
where both polymers are crosslinked.29, 30 In the semi-IPNs of chitosan and PNIPAM,
PNIPAM is typically the polymer that is crosslinked, either with tetraethylene glycol
diacrylate (TEGDA) or methylene bis-acrylamide; however, toxicity issues could arise
with these small linker crosslinkers.29 Chitosan has been crosslinked when combined
with PNIPAM in a semi-IPN, but it has been crosslinked with the more toxic
glutaraldehyde, not genipin.31
In this in vitro investigation, we evaluated the properties of genipin crosslinked
chitosan sponges and genipin crosslinked chitosan sponges with PNIPAM for a local
antibiotic delivery system. The sponges’ degradation properties were ascertained to
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determine in vitro degradation timing and Fourier Transform Infrared Spectroscopy
(FTIR) analysis was conducted to examine the crosslinking reaction of the chitosan
sponges. To determine if the sponges could effectively release the antibiotics,
vancomycin and amikacin, and inhibit the growth of infectious bacteria, the antibiotic
uptake, elution, and activity against specific strains of S.aureus and P. aeruginosa were
studied. In order to assess short term cytotoxicity, the impact of the sponges and
antibiotic eluates on the cell viability of 3T3 fibroblasts was evaluated.

3.2

Materials and Methods

Materials
Chitosan powder at 71% degree of deacetylation (DDA) with 1480 cP intrinsic
viscosity and approximately 426,800 g/mol molecular weight was obtained from Primex
(Iceland) and genipin was obtained from Wako (Richmond, VA). Poly (nisopropylacrylamide) (PNIPAM) with a molecular weight of approximately 10,00015,000 g/mol was purchased from Sigma Aldrich (St. Louis, MO). All other reagents
were purchased from Fisher Scientific (Pittsburg, PA) and were of analytical grade.
Vancomycin, amikacin, and 2 x crystallized chicken white egg lysozyme were obtained
from MP Biomedicals (USA) and trypticase soy broth (TSB) was purchased from
Beckton, Dickinson, and Company (Franklin Lakes, NJ). NIH 3T3 mouse fibroblasts
were purchased from ATCC (Manassas, VA). Dulbecco’s Modified Eagle Medium
(DMEM), fetal bovine serum (FBS), and 100x penicillin (10,000 units/mL), streptomycin
(10 mg/mL), and amphotericin B (25 µg/mL) solution were purchased from Fisher
Scientific. The Live/Dead® stain kit for mammalian cells and the Cell Titer-Glo®
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Luminescent Cell Viability assay were obtained from Invitrogen (Carlsbad, CA) and
Promega (Madison, WI), respectively.
Sponge Preparation
Three different chitosan sponge test groups were created: an uncrosslinked
chitosan sponge (control), a genipin crosslinked chitosan sponge (genipin crosslinked),
and a sponge with genipin crosslinked chitosan mixed with PNIPAM (PNIPAM/genipin
crosslinked) To create the sponges, a 1% (w/v) chitosan solution was prepared by
dissolving the chitosan powder in 1% (v/v) blended lactic/ acetic acid (75:25), under
constant stirring for 24 hours. In order to remove any insoluble chitosan from the
solution, the solution was filtered through a 180 µm nylon screen and allowed to degas at
ambient temperature for approximately one hour. For the uncrosslinked chitosan
sponges, 20 mL of the filtered 1% (w/v) chitosan solution was cast into separate fluted
aluminum weighing dishes (Fisher Scientific, 42 mL) and placed into a -80°C freezer
(C90-14A31; Kendro Lab Products, Asheville, NC) for one hour.
In order to crosslink the chitosan, genipin was added to the 1 % (w/v) filtered
chitosan solution in order to reach a genipin concentration of 5 mM, determined from
previous formulation research. The genipin and chitosan solution was stirred for 3.5
hours at 35°C before 20 mL of the solution was cast into aluminum weighing dishes and
placed in the -80°C freezer for one hour. As the crosslinking time increased, a blue color
developed in the genipin and chitosan solution. To make sponges from genipin
crosslinked chitosan and PNIPAM, PNIPAM was added to deionized water to reach 0.4%
(w/v), a concentration determined from previous formulation research. Lactic acid, acetic
acid, and chitosan were then added to the PNIPAM and deionized (DI) water solution in
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order to reach a solution of 1 % (w/v) chitosan, 1% (v/v) blended acid (75:25 lactic to
acetic acid), and 0.4% (w/v) PNIPAM. After mixing for 24 hours, the chitosan and
PNIPAM solution was filtered through a 180 µm nylon mesh. Next, genipin was added
to the solutions to reach a concentration of 5 mM, solutions constantly mixed for 1.5
hours and then degased at ambient temperature for approximately one hour. The
PNIPAM/ genipin crosslinked chitosan solution was cast into separate aluminum
weighing dishes in 20 mL amounts, covered with parafilm, and allowed to continue
crosslinking at ambient temperature for a cumulative 24 hours of crosslinking. The same
blue color development seen in the genipin crosslinked chitosan sponges appeared in the
PNIPAM/genipin and chitosan solution and the solutions were placed into a -80°C
freezer for one hour.
After all three types of sponges were frozen at -80°C for one hour, they were
removed from the freezer and placed into a freeze-dryer (FreeZone 2.5; Labconco,
Kansas City, MO) for 48 hours. The sponges were removed after lyophilization and
soaked in 0.2 sodium hydroxide (NaOH) solution and rinsed in distilled water until
neutral pH was achieved. However, the sponges used in the direct contact cytotoxicity
testing were soaked in 1 M NaOH because of residual acidity in the uncrosslinked
chitosan sponges. The hydrated sponges were refrozen at -80°C for one hour and then
relyophilized for 48 hours. The sponges were removed and sterilized by low dose
gamma irradiation (25.9-29.6 kGy).

25

Sponge Degradation
To measure the effect of crosslinking on the degradation, unloaded uncrosslinked,
genipin crosslinked, and PNIPAM/genipin crosslinked chitosan sponges, were subjected
to degradation testing. Samples with an approximate initial dry weight of 30.30 mg were
obtained from three replicate sponges of each type. One sample from each replicate
sponge type was measured for change in mass at each time point. Pieces of dehydrated
uncrosslinked and crosslinked chitosan sponges were weighed on a Mettler Toledo
XS205 Dual Range scale (Columbus, OH) and then submerged in 10 mL of phosphate
buffered saline (PBS) supplemented with 100 µg/mL lysozyme, 100 units/mL penicillin,
0.1 mg/ml streptomycin, 0.25 µg/mL amphotericin B. Lysozyme is an enzyme present in
the human body and has shown to quickly degrade chitosan in vitro.32 The samples were
incubated at 37°C for six weeks and samples (n=3/group) were taken at 1, 2, 3, and 6
weeks. In order to maintain sufficient lysozyme activity, the lysozyme solution was
completely refreshed each week. At each time point, the lysozyme solution was removed
and the sponges were washed with 10 mL deionized water, in order remove any residual
salts from the PBS. To remove the deionized water wash solution, the sponges were
placed in fluted aluminum weighing dishes, with known weights, in a convection oven at
30°C for one hour. After one hour, the sponges were placed in a dessicator for 24 hours
and the new sponge weights were measured. The percent of the sponge remaining at
each time point was determined using the following equation:

Percent remaining

ponge weight at x weeks
Initial dry sponge weight
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Evaluation of Crosslinking
The presence of crosslinking in the chitosan sponges was determined by Fourier
Transform Infrared Spectroscopy (FTIR). FTIR spectra of the sponges were recorded
using diffuse reflectance (DRIFT) FTIR on a Nicolet Magna IR Spectrometer 550
(ThermoScientific) with a helium neon class II laser. The sponges were ground into
powder, dried in a convection oven at 30°C, and combined with potassium bromide. The
spectra were acquired with 64 scans and a resolution of 4 cm-1 and OMNICTM software
was used to analyze the results.
Antibiotic Uptake and Elution
Because wound infections are often polymicrobial with both Gram-positive and
Gram-negative bacteria present, both single and dual antibiotic loaded sponges were
tested. To determine the sponges’ antibiotic uptake and elution characteristics, 5 mg/ml
solutions or either vancomycin, amikacin, or both 5 mg/ml vancomycin and 5 mg/ml
amikacin were loaded into sponges. Using three replications of each sponge type for
each of the three antibiotic solutions, sponges of known weights were submerged in 10
mL of the antibiotic solution for one minute. After one minute, the sponge was removed
and the volume of unabsorbed antibiotic solution was measured. The volume of
antibiotic uptake was normalized by the sponge weight.
Immediately after the 1 minute in situ antibiotic loading, the sponges were
completely submerged in 20 mL of sterile PBS and incubated at 37°C. At 1, 3, 6, 24, 48,
72, and 96 hours the PBS was completely refreshed, saving 1 mL aliquots at -20°C for
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analysis of released antibiotics.

Fluorescence polarization immunoassay (TDxFLx;

Abbott Labs; Abbott Park, IL) was utilized to quantify the concentration of antibiotics
eluted from the sponges with amikacin and vancomycin specific reagent kits.
Antibiotic Activity
The specific antibiotic activity of the eluates against S. aureus (Cowan I strain)
and P. aeruginosa (ATCC 27317) was tested using turbidity assays. Dilutions (1:10) of
vancomycin eluates were tested against S. aureus and 1:10 dilutions of amikacin eluates
were tested against P. aeruginosa. Vancomycin eluates were added in two hundred
microliter amounts to 1.75 mL of trypticase soy broth (TSB) along with 50 µL inoculum
of S. aureus containing approximately 2x106 colony forming units (CFU). Amikacin
eluates (200 µL) were added to 1.75 mL of TSB and 50 µL inoculum of P. aeruginosa
containing approximately 2x106 CFU. Positive controls with bacteria but no antibiotic
eluates and negative controls with only sterile TSB were also prepared. All samples were
mixed and incubated at 37°C for 24 hours. After incubation, the samples were mixed
again and the absorbance at 530 nm was recorded.
In vitro cytotoxicity
For cytotoxicity testing of the antibiotic eluates from the sponges, NIH 3T3
fibroblasts were grown in DMEM, supplemented with 100 units/mL penicillin, 0.1 mg/ml
streptomycin, 0.25 µg/mL amphotericin B, and 20% FBS in an incubator at 37°C and 5%
CO2. Twenty percent FBS was used instead of 10% FBS because of eventual dilution of
the serum with the antibiotic eluates. The cells were then seeded at 3 x 104 cells/cm2 in
96 well plates made of tissue culture polystyrene (TCP) and allowed to attach overnight .
Each antibiotic eluate from each elution time point (n = 3) from the sponges and a
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negative control of sterile 1 x PBS solution (n = 9) were added in 100 µl volumes to the
wells containing cells and growth media, for a total of 200 µl of media and eluate or PBS
in each well, and allowed to incubate for 24 hours.

After incubation, the culture media

was removed and replaced with serum free DMEM and an equal volume of Cell TiterGlo® Reagent Solution. The cell solutions were transferred into opaque 96 well plates
and the luminescence was read at 590 nm in a 96 well plate reader (Bio-Tek Instruments
Inc; Ontario, Canada). The results were reported as cells/cm2, which was determined
from a standard curve generated by a known dilution of cells.
Direct contact assay using NIH 3T3 fibroblasts was used to evaluate any potential
cytotoxicity of the experimental crosslinked sponges as compared to control sponges.
Cells were grown in DMEM, supplemented with 10% FBS, and 100 units/mL penicillin,
0.1 mg/ml streptomycin, 0.25 µg/mL amphotericin B. The cells were seeded at 3 x 104
cells/cm2 in 48 well TCP cell culture plates and allowed to attach for 24 hours to establish
a monolayer. A standard size hole punch (2” Reach Punchline; McGill, Inc.; Marengo,
IL) was used to cut 6 mm in diameter samples of each sponge with an average weight of
approximately 6 mg. The samples (n = 3 for each sponge type) were soaked in
approximately 2 ml of 70% ethanol for over one hour and then rinsed with sterile PBS,
warmed to 37°C, four times. The third PBS rinse was extended to 30 minutes so that
any remaining ethanol could be removed through diffusion. The sponges were placed in
direct contact with the cell monolayer. Polytetrafluoroethylene (PTFE) disks, with a 6
mm diameter and 4 mm thickness were utilized as controls. After 24 hours of incubation
at 37°C and 5% CO2, the culture media was removed and replaced with serum free
DMEM and an equal volume of Cell Titer-Glo® Reagent solution. The cell solutions
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were transferred to an opaque 96 well plate and the luminescence was read at 590 nm on
a plate reader. The results were reported as cells/cm2 determined from a standard curve
generated by a known number of cells and percent cell viability, with the cells exposed to
the PTFE disks as 100% viable cells. Live/Dead® staining was also utilized to
qualitatively assess the cells’ viability (n = 2) and was conducted at 100 x magnification
with a fluorescent light microscope (Nikon Eclipse ® TE300; Tokyo, Japan), a digital
camera (Q Imaging Retiga Fast Color ® 1394; British Columbia, Canada) and imaging
computer software (BioQuant OSTEO II ®; Nashville, TN). Green and red fluorescence
of cells, from the calcein AM and Eth D-1 reagent staining, indicated viable and non
viable cells, respectively.
Statistical Analysis
All quantitative data are expressed as mean ± standard deviation ( n ≥ 3 for all
groups). Two way analysis of variance (ANOVA) was used on data from degradation,
antibiotic uptake, elution, and eluate cytoxicity testing to determine the differences
between antibiotic or time and sponge independent variables and one way ANOVA was
utilized on sponge cytotoxicity data. If statistically significant differences were detected,
then the Holm-Sidak post hoc analysis was used for multiple comparisons. Analysis was
performed using 2004 SigmaStat (San Jose, CA) and Microsoft Excel software
(Microsoft, Inc, Redmond, WA) and p < 0.05 was considered statistically significant.

3.3

Results
The results of the degradation study are shown in Figure 1, demonstrating the

percent remaining of the mass of the original uncrosslinked and crosslinked chitosan
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sponges. Both types of crosslinked sponges exhibited statistically significant differences
from the uncrosslinked chitosan control sponges at each time point (p < 0.0001), and
from each other at week 3 (p = 0.014). Statistically significant differences in degradation
over time appeared at week 6 in the genipin crosslinked and PNIPAM/ genipin
crosslinked sponges (p < 0.0001). The uncrosslinked sponges demonstrated a fast initial
degradation, with only an average of 4.49 ± 2.58 weight (wt) % remaining at week one
and an average of 2.62 ± 1.17 wt% remaining at week six. Both types of crosslinked
sponges showed a slower degradation, with 78.8 ± 1.15 and 73.9 ± 1.27 wt% remaining
at week one and 64.74 ± 6.50 and 60.96 ± 0.80 wt% remaining at week six in the genipin
crosslinked and PNIPAM/ genipin crosslinked sponges, respectively.

p = 0.014

Perceent Remaining (%)

90
80

†

70

†

60
50
40
30
20
10

**

**

**

**

0
1
Uncrosslinked

2

3
6
Time (weeks)
Genipin crosslinked
PNIPAM/ genipin crosslinked

Figure 1. The degradation of uncrosslinked and crosslinked chitosan sponges without
antibiotics in 100 µg/ml lysozyme solution represented as mean ± standard deviation.
n = 3 for all groups (** vs. all others, p < 0.0001; † vs. other timepoints in same sample,
p < 0.0001)
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Infrared spectra of uncrosslinked and crosslinked chitosan sponges are shown in
Figure 2. Significant absorbance was observed at 1739, 1576, 1472, 1210, 1052, 921,
and 669 cm-1. The peaks at 1576 and 1210 cm-1 were assigned to primary amine
scissoring and C-N stretching in aliphatic amines, respectively. The peak at 1052 cm-1
corresponded to C-O stretching and the 669 cm-1 peak was assigned to N-H wag in
primary and secondary amines. The absorbance peaks at 1472, and 921 cm-1 did not
correspond to peaks previously found to be associated with genipin crosslinking of
chitosan.27

1576

669

0.090
0.085

1210

0.080

1052

0.075
0.070
0.065
0.060

(b)

Abs orbance

0.055
0.050

(a)

0.045
0.040
0.035
0.030
0.025

(c)

0.020
0.015
0.010
0.005
0.000
1800

1600

1400

1200

1000

800

600

Wavenumbers (cm-1)

Figure 2. FTIR spectra of (a) uncrosslinked chitosan sponge (blue), (b) genipin
crosslinked chitosan sponge (purple), and (c) PNIPAM/genipin crosslinked chitosan
sponge (red) (n = 2 for all groups)
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The absorbance peaks at 1739 and 1576 cm-1 decreased slightly upon the addition
of genipin to the chitosan sponges and decreased significantly from the addition of
PNIPAM and genipin to the chitosan sponges. Decreases in absorbance were also
measured for the peak at 1052 cm-1 from the incorporation of PNIPAM and genipin, as
well as genipin alone, into the uncrosslinked sponges, accompanied by an increase in
absorbance at 669 cm-1 from crosslinking the chitosan sponges. The absorbance peak at
1210 cm-1 exhibited an increase in absorbance from the addition of PNIPAM and genipin
into the chitosan sponges, and a decrease in absorbance from the addition of only genipin
to the uncrosslinked chitosan sponges.
The uptake of vancomycin, amikacin, and dual loaded vancomycin and amikacin
solutions by the uncrosslinked and crosslinked chitosan sponges is reported as milliliters
of antibiotic solution absorbed in one minute per gram of chitosan sponge (Figure 3).
The uncrosslinked, genipin crosslinked, and PNIPAM/genipin crosslinked chitosan
sponges absorbed an overall average of 2.78 ± 1.19, 5.44 ± 1.35, 5.74 ± 0.61 mL/min of
antibiotic solution (non-normalized to weight), respectively. Both types of crosslinked
chitosan sponges exhibited significantly higher antibiotic uptake (mL/min/g) than the
uncrosslinked chitosan sponges (p < 0.0001), but both the genipin crosslinked sponges
and the PNIPAM / genipin crosslinked sponges were statistically similar. There were no
statistically significant differences between antibiotics absorbed in each sponge type
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Figure 3. The antibiotic uptake of vancomycin, amikacin, and dual loaded vancomycin
and amikacin solutions by uncrosslinked and crosslinked chitosan sponges, normalized to
sponge weight, represented as mean ± standard deviations ( n = 4 for all groups). The
uncrosslinked chitosan sponges absorbed significantly less antibiotic solution than both
types of crosslinked sponges (*vs all other crosslinked sponges, p < 0.001).

The elution studies indicated that the all three types of sponges eluted the highest
levels of vancomycin and amikacin at the 1 hour time point, after which the antibiotic
release levels were reduced (Figures 4 and 5). The PNIPAM/genipin crosslinked chitosan
sponges, either single loaded, dual loaded, or both, eluted significantly higher quantities
of vancomycin than the uncrosslinked chitosan sponges through 96 hours (Figure 4). The
PNIPAM/ genipin crosslinked chitosan sponges also released significantly more
vancomycin than the genipin crosslinked sponges from 24 hours to 96 hours of antibiotic
release. The dual loaded PNIPAM/ genipin crosslinked chitosan sponges also eluted
significantly more amikacin than the uncrosslinked chitosan sponges from 24 hours
through 96 hours (Figure 5).
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Figure 4. The vancomycin elution from (A) 1 to 96 hours and (B) an expanded view of
48 to 96 hours from uncrosslinked and crosslinked chitosan sponges, both single and dual
loaded, represented as mean ± standard deviation (n = 3 for all groups). (* vs. each other,
p ≤ 0.001; † vs. each other, p ≤ 0.003; ** vs. all others, p ≤ 0.001)
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Figure 5. The amikacin elution from (A) 1 to 96 hours and (B) an expanded view of 48
to 96 hours from uncrosslinked and crosslinked chitosan sponges, both single and dual
loaded, represented as mean ± standard deviation (n = 3 for all groups). (* vs. each other,
p ≤ 0.001; † vs. each other, p ≤ 0.003; ** vs. all others, p ≤ 0.001)
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The PNIPAM/genipin crosslinked sponges exhibited a higher percent total release of
single loaded vancomycin and amikacin that was loaded into the sponges than the
uncrosslinked and genipin crosslinked sponges, but did not elute more dual loaded
vancomycin and amikacin than the other two sponge types (Table 1).

Table 1. Total % release of antibiotics from uncrosslinked and crosslinked sponges (n =
3 for all groups)
Genipin
PNIPAM/genipin
Uncrosslinked crosslinked
crosslinked
Vancomycin Single Loaded 74.64 ± 29.99
71.87 ± 10.87
100 ± 4.68
Amikacin Single Loaded
87.24 ± 12.22
83.23 ± 4.93
89.78 ± 10.03
Vancomycin and Amikacin 90.45 ± 33.69
94.05 ± 7.54
93.53 ± 1.60

From activity testing, the vancomycin eluates from the uncrosslinked chitosan
sponges, both single and dual loaded, demonstrated sufficient activity against S. aureus
with no bacterial growth through 24 hours (Table 2). Vancomycin eluates from genipin
crosslinked sponges and PNIPAM/genipin crosslinked sponges were active against S.
aureus through 48 and 72 hours, respectively. Amikacin eluates from single loaded
uncrosslinked sponges, dual loaded genipin crosslinked sponges, and both single and dual
loaded PNIPAM/ genipin crosslinked sponges were active against P. aeruginosa through
24 hours (Table 3). Eluates from the dual loaded uncrosslinked sponges and single
loaded genipin crosslinked chitosan sponges only inhibited bacterial growth through 6
hours.
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Table 2. Average activity of 1:10 dilutions of vancomycin eluates from uncrosslinked
and crosslinked chitosan sponges against S. aureus (n = 3 for all groups)
Staphylococcus aureus
Time (hours)
Sponge type
Loading 1
3
6 24 48
72
96
Uncrosslinked chitosan

Single

Uncrosslinked chitosan

Dual

Genipin crosslinked chitosan

Single

Genipin crosslinked chitosan

Dual

PNIPAM/genipin crosslinked chitosan Single

-

-

-

-

PNIPAM/genipin crosslinked chitosan Dual
(-) represents no bacterial growth detected (+) bacterial growth detected

+
+
-

+
+
+
+
-

+
+
+
+
+
+

Table 3. Average activity of 1:10 dilutions of amikacin eluates from uncrosslinked and
crosslinked chitosan sponges against P. aeruginosa (n = 3 for all groups)
Pseudomonas aeruginosa
Time (hours)
Sponge type
Loading 1 3
6
24
48 72 96
Uncrosslinked chitosan

Single

-

-

-

-

+

+

+

Uncrosslinked chitosan

Dual

-

-

-

+

+

+

+

Genipin crosslinked chitosan

Single

-

-

-

+

+

+

+

Genipin crosslinked chitosan

Dual

-

-

-

-

+

+

+

-

-

-

-

+

+

+

+

+

+

PNIPAM/ genipin crosslinked chitosan Single

PNIPAM/ genipin crosslinked chitosan Dual
(-) represents no bacterial growth detected (+) bacterial growth detected
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The effects of the vancomycin and amikacin eluates, both single and dual loaded,
from the uncrosslinked and crosslinked chitosan sponges on 3T3 fibroblasts after 24
hours of exposure are shown in Figure 6. All three types of antibiotic eluates,
vancomycin single loaded, amikacin single loaded, and vancomycin and amikacin dual
loaded, exhibited similar effects on the number of cells as compared to the PBS control
from 3 to 96 hours. In the single loaded vancomycin and amikacin eluates from the
PNIPAM/ genipin crosslinked sponges, there was even a consistent growth of cells
beyond the PBS control and the eluates from the uncrosslinked and genipin crosslinked
chitosan sponges. At 1 hour, the highest antibiotic elution concentration, there were
significantly fewer cells, as compared to the PBS control, from all three types of
antibiotic eluates released from all three sponges. This lower cell number corresponds to
higher levels of antibiotics present in the first time point, which have been reported to be
cytotoxic at high levels.33
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Figure 6. Number of viable cells determined with Cell-Titer Glo® assay after 24 hours
of exposure to (A) vancomyin eluates, (B) amikacin eluates and (C) dual loaded
vancomycin and amikacin eluates from uncrosslinked and crosslinked chitosan sponges
represented as mean ± standard deviation. n = 3 for all groups (** vs. all others, p ≤
0.001; *, p≤ 0.001; †, p ≤ 0.003)
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Figure 6. Number of viable cells determined with Cell-Titer Glo® assay after 24 hours
of exposure to (A) vancomyin eluates, (B) amikacin eluates, and (C) dual loaded
vancomycin and amikacin eluates from uncrosslinked and crosslinked chitosan sponges
represented as mean ± standard deviation. n = 3 for all groups (** vs. all others, p ≤
0.001; *, p≤ 0.001; †, p ≤ 0.003)

The effect on cell viability after 24 hours of direct contact to uncrosslinked and
crosslinked chitosan sponges, with no antibiotics loaded, is provided in Table 4. All
three types of sponges exhibited higher number of cells than the control biomaterial,
PTFE, with significant differences between the uncrosslinked and PNIPAM/genipin
crosslinked sponges and PTFE (p< 0.0001). Significant differences were also seen
between the uncrosslinked and genipin crosslinked chitosan sponge (p = 0.00053).
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Table 4. Cell viability, determined by Cell-Titer Glo® assay, after 24 hours of exposure
to uncrosslinked and crosslinked chitosan sponges, and PTFE disks
Sample
Viable cells (cells/cm2)
Cell Viability (%)
Uncrosslinked†
107585 ± 3474
140.05 ±4.52
Genipin crosslinked†
88273 ± 7438
114.91 ±9.68
PNIPAM/genipin crosslinked
99335 ± 15022
129.31 ± 19.56
PTFE control*
76816 ± 7964
100 ± 10.37
Data represented as mean ± standard deviation (n = 3 for all groups), a Cells exposed to
PTFE corresponded to 100 cell viability (†, p = 0.00053; * vs. all others except genipin
crosslinked, p < 0.0001)

Live/Dead® staining also revealed that the cells exposed to the uncrosslinked and
crosslinked chitosan sponges exhibited similar cell shape and viability as the cells
exposed to the PTFE disks (Figure 7). The uncrosslinked and crosslinked chitosan
sponges exhibited low cytotoxicity, as indicated by the few number of dead cells present
in all samples.
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(A)

(B)

(C)

(D)

(A)
(C)

(B)
(D)

(E)
(E)
Figure 7. Representative
fluorescence overlay images of 3T3 fibroblasts adjacent to test
samples with Live/Dead® stain after 24 hours of exposure to (A) uncrosslinked chitosan
sponge, (B) genipin crosslinked chitosan sponge, (C) PNIPAM/ genipin crosslinked
chitosan sponge, and (D) PTFE disk (known biomaterial control); green and red represent
viable and non viable cells, respectively. (100x magnification)

3.4

Discussion
The treatment of musculoskeletal infections is becoming complicated by the

increased emergence of antibiotic-resistant bacteria and increases the need for local drug
delivery over systemic delivery. The current local delivery systems have their
drawbacks, including burst release, possible biofilm formation, need for surgical removal,
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and the formation of sterile draining sinuses.12, 14, 15, 20 This in vitro study proposes the
creation of a local drug delivery system with tailorable elution and degradation
properties, by crosslinking chitosan sponges either with genipin alone, or as a semi- IPN
with genipin crosslinking and PNIPAM incorporation. These crosslinked sponge
delivery systems need to be degradable, able to absorb and elute biologically active
antibiotics , and exhibit low cytotoxicity.
In order to determine sponge degradation, the in vitro degradation properties were
investigated. The finding of this study was that both genipin crosslinked and
PNIPAM/genipin crosslinked chitosan sponges degrade slower with 64.74 ± 6.50 and
60.96 ± 0.80 wt% remaining respectively, in comparison to 2.62 ± 1.17 wt% of the
uncrosslinked chitosan sponges remaining at week six. No previous reported studies
have evaluated the in vitro degradation properties of genipin crosslinked chitosan
sponges. However, these results follow the same trend reported in an in vivo study of
uncrosslinked and glutaraldehyde or genipin crosslinked chitosan microspheres.34 Mi
and researchers found that, after intramuscular injection of chitosan microspheres into the
skeletal muscle of Wistar rats, the uncrosslinked and glutaraldehyde crosslinked chitosan
microspheres were severely degraded at 20 weeks post-operation, while the genipin
crosslinked microspheres were significantly less degraded.34 While the slower
degradation in the crosslinked sponges was expected, the degradation of the
uncrosslinked chitosan sponges is much higher than values reported for chitosan films
and sponges found in previous reports.32, 35, 36 Slow or rapid sponge degradation can
impact active agent elution and the response of pathogenic bacteria within a wound.37
Tomihata and researchers reported films of 1 wt% chitosan (73% DDA) in 1% acetic acid
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to have approximately 90 wt% remaining after 50 hours in 4 mg/ml lysozyme solution.32
Another study found films made from 1.5 wt% chitosan in 1% lactic acid and 1% acetic
acid to have approximately 50 wt% and 25 wt% remaining after 100 hours in 100 µg/ml
lysozyme solution. 35 Smaller lyophilized 1 wt% chitosan sponges (5 x 10 mm) had 18.08
± 4.28 % weight loss after 24 hours in 8 mg/ml lysozyme solution.36
In order to determine that crosslinking of the chitosan sponges occurred, FTIR
spectra were obtained from all three sponge types. The increase in absorbance of the NH wag peak at 669 cm-1 from primary and secondary amines in the spectra of the
crosslinked sponges, as compared to the uncrosslinked, could illustrate an increase in
secondary amine groups in the amide linkages during crosslinking. As seen in
previously reported research, the crosslinking reaction is demonstrated by the decrease in
absorbance of the primary amine peak at 1576 cm-1 and the C-O stretching peak at 1052
cm-1.27 When crosslinking occurs, the chitosan loses primary amines and the ester group
in genipin is converted to amide linkages.27, 38 Oxygen radical-induced polymerization of
genipin could explain the decrease in absorbance of the C-N stretching peak at 1210 cm-1
with the addition of genipin to the chitosan sponge. The green/blue color development as
crosslinking occurred could also be an indicator of the genipin polymerization, or simply
the reaction of genipin with primary amines.27, 38
Antibiotic uptake and elution are two of the most important properties for a local
drug delivery device and have been investigated in many chitosan delivery systems,
including sponges20, microspheres23, 39, hydrogels31, and films35.

It has been previously

reported that point of care antibiotic loading, loading of antibiotics during surgery or
treatment, of local drug delivery systems provides the advantage of the physician’s
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ability to select an antibiotic based on the patient’s needs.40 The similar values in
antibiotic uptake between both crosslinked sponges suggests that the increase in
antibiotic uptake, compared to the uptake in the uncrosslinked sponges, is due more to the
genipin crosslinking than to the presence of PNIPAM. Noel et al previously reported
vancomycin and amikacin uptake to be approximately 7 mL/min in uncrosslinked
chitosan sponges constructed with 25 mL of 1% (w/v) chitosan solution; however, after
the normalization of uptake to approximate sponge weight, the uptake values of both
antibiotics in the uncrosslinked sponges are similar to those reported in this research.20
The increase in antibiotic uptake in both of the crosslinked chitosan sponges
corresponds to an overall increase in antibiotic elution as well. The results of this elution
study differ from previous research with antibiotic or albumin pre-loaded genipin
crosslinked chitosan microspheres; as crosslinking increased the overall antibiotic or
protein release decreased.23, 39 However, this difference is expected because the
antibiotic and protein were both pre-loaded during construction of the microspheres, as
opposed to point of care loading after the microspheres were created. In another reported
study, the overall drug release increased as glutaraldehyde crosslinking increased in fullIPN hydrogels of bis(acrylamide) crosslinked PNIPAM and glutaraldehyde crosslinked
chitosan with point of care loading.31 The concentration of vancomycin released after 1
hour from the uncrosslinked, genipin crosslinked, and PNIPAM/genipin crosslinked
chitosan sponges in this study is approximately 75, 40.8, and 16.2% lower than
vancomycin released after 1 hour, 1007.4 ± 162.8 µg/ml, from uncrosslinked sponges
previously reported in the Noel study.20 The same study reported the uncrosslinked
chitosan sponges released 881.5 ± 15.4 µg/ml of amikacin after 1 hour, which is
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approximately 52, 8, and 18% higher than the amikacin released from the uncrosslinked,
genipin crosslinked, and PNIPAM/genipin crosslinked sponges in this study,
respectively.

However, if the previously reported elution values from the Noel study are

normalized to approximate sponge weight, there should be no significant differences
from this research.20
The biologic activity of the eluted vancomycin and amikacin was verified by
measuring the effective activity against specific strains of S. aureus and P. aeruginosa,
with MICs of 0.5 – 1 µg/ml and 4 µg/ml, respectively.20 The single loaded vancomycin
eluates from the uncrosslinked, genipin crosslinked, and PNIPAM/ genipin crosslinked
chitosan sponges inhibited growth of S. aureus through 24, 48, and 72 hours,
respectively. Single loaded amikacin eluates from the uncrosslinked, genipin
crosslinked, and PNIPAM/ genipin crosslinked chitosan sponges inhibited growth of P.
aeruginosa through 24, 6, and 24 hours, respectively. Noel et al previously reported that
vancomycin and amikacin eluates from uncrosslinked chitosan sponges inhibited S.
aureus and P. aeruginosa through 72 and 48 hours, respectively.20 However, the longer
inhibition times correspond to higher levels of antibiotics released from larger sponges,
and after normalization to sponge weight, the inhibition times would be similar to the
inhibition found in this study, based on the MIC levels. 20 As previously mentioned, the
activity assay was conducted with a 1:10 dilution of the antibiotic eluates; this dilution
factor accounted for bacterial growth when original eluates were above MIC levels.
The cytotoxicity testing of the sponges and the antibiotic eluates was investigated
in order to assess the biocompatibility of the sponges, the antibiotics, and any potential
leachable substances from the sponges.

The direct contact cytotoxicity test with the
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sponges resulted in viable cells and low cytotoxicity when exposed to all three sponge
types for 24 hours. Cell viability percentages for L929 fibroblasts exposed to genipin
crosslinked chitosan and silk fibroin sponges for 24 hours were previously reported to be
79.1 ± 13.3, 53.5 ± 21.1, and 69.5 ± 29.7% cell viability for sponges with 80/20, 50/50,
and 20/80 chitosan to silk ratios, respectively.28 However, the reported cell viability
percentages were calculated with cells grown directly on tissue culture plastic as the
control 100% cell viability.28 When cells exposed to PTFE controls represent 100% cell
viability, the previously reported cell viability percentages are similar to the cell viability
percentages for the uncrosslinked, genipin crosslinked, and PNIPAM/genipin crosslinked
sponges in this study.28 The increased number of viable cells exposed to the
uncrosslinked and crosslinked sponges compared to the PTFE control could be caused by
the increased structural porosity in the sponges versus the solid PTFE disks. The
cytotoxicity test with the antibiotic eluted from the sponges also resulted in viable cells
and low cytoxicity. The PNIPAM/genipin crosslinked chitosan sponge eluates resulted in
a large number of viable cells, indicating that the PNIPAM/genipin crosslinked chitosan
sponges harbor a favorable environment for cell proliferation with these study conditions.

3.5

Summary and Conclusions
This in vitro study demonstrates that crosslinking chitosan sponges with genipin

or genipin and PNIPAM creates novel, point of care antibiotic loaded, crosslinked
sponges which exhibit potential for use as a degradable adjunctive therapy for
musculoskeletal infection control. Crosslinking chitosan sponges with genipin and
genipin crosslinking in the presence of PNIPAM resulted in an increase in vancomycin
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and amikacin uptake, release of antibiotics for improved bactericidal efficacy against
known pathogens, and a decrease in degradation, as compared to uncrosslinked chitosan
sponges. The crosslinking of the chitosan sponge appears beneficial when a slower
degradation or an increased release of vancomycin or amikacin is desired, and the
addition of PNIPAM to genipin crosslinked chitosan sponges even further increases, and
sustains, the release of vancomycin or amikacin. The novel crosslinked chitosan sponges
and their antibiotic eluates elicited minimal cytotoxic response from cells, similar to other
biomaterials. Limitations of this study are, 1) the short duration of the cytotoxicity study,
2) the biologic activity assays were only conducted against planktonic bacteria, not
adherent bacteria typically associated with biofilms, and 3) the translation of in vitro
research results to in vivo efficacy. For an accurate evaluation of clinical performance, in
vivo studies with the crosslinked chitosan sponges should be pursued in the future. In
order to fully characterize the properties of the crosslinked sponge delivery systems,
further investigations into the swelling and more extended degradation and elution
studies of the sponges are needed.
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CHAPTER 4:
CONCLUSIONS
In this preliminary in vitro study, novel genipin crosslinked sponges and sponges
made from a semi-interpenetrating network of genipin crosslinked chitosan and poly(nisopropylacrylamide) were developed for potential use as nontoxic, degradable, local
drug delivery systems to minimize or treat musculoskeletal infections. Both crosslinked
sponges demonstrated decreased degradation, when compared to the uncrosslinked
chitosan sponges. The genipin crosslinked and PNIPAM/genipin crosslinked sponges
absorbed and released more vancomycin and amikacin than the uncrosslinked sponges.
The incorporation of PNIPAM into a genipin crosslinked sponge also prolonged the
release of both antibiotics and the antibiotics’ corresponding specific biologic activity.
The antibiotic eluates from all of the sponges exhibited effective biologic activity against
the known musculoskeletal pathogens, Staphylococcus aureus and Pseudomonas
aeruginosa, and, along with the sponges, did not induce any short term cytotoxic effects.
The preliminary in vitro data from this study demonstrates that the incorporation
of the nontoxic crosslinker genipin, either alone or with the thermo-responsive polymer
PNIPAM, into chitosan sponges creates tailorable drug delivery systems that may show
future promise for in vivo studies and translation to clinical evaluations. The ability of a
physician to select a type of sponge, antibiotic, and antibiotic concentration based on a
patient’s needs could potentially result in faster and more efficacious treatment of
infections, and even a possible reduction of antibiotic resistance development in the
patient. While additional in vivo and in vitro studies are needed in order to assess the true
effectiveness and long term biocompatibility of these crosslinked sponges, this
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preliminary study has demonstrated that crosslinking chitosan sponges, with genipin and
PNIPAM and genipin, is beneficial when a more sustained degradation and antibiotic
elution time is desired.
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CHAPTER 5:
FUTURE WORK
In order to fully evaluate the properties of the crosslinked sponges, additional in
vitro materials characterization tests are needed, including swelling measurements, more
extended degradation studies with non loaded and antibiotic loaded sponges, and more
extended elution studies, with additional antibiotics. The bioadhesive strength of the
sponges when loaded with PBS and antibiotics also needs to be assessed, with a greater
number of samples. Long term cytotoxicity and cell proliferation tests would provide
beneficial information about the impact of the sponges on cells before additional in vivo
tests are conducted. Specifically, an in vivo degradation study in rats would provide a
more accurate degradation profile of the sponges and local tissue response. In addition to
an in vivo degradation study, a proof of principle infected mouse catheter animal model
would demonstrate the true efficacy of sponges as a local antibiotic delivery system
preventing and treating bacterial infections.
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APPENDIX A:
Crosslinking Chitosan Sponges with Dimethyl 3, 3 dithio bis propionimidate
(DTBP)
Introduction
Chitosan hydrogels have also been successfully crosslinked through disulfide
bridges with dimethyl 3, 3 dithio bis propionimidate (DTBP), but the hydrogels were not
in a lyophilized sponge form.62 Crosslinked chitosan hydrogel scaffolds prepared with
DTBP exhibited similar properties to glutaraldehyde crosslinked chitosan scaffolds, but
showed greater strength and less toxicity.62 Therefore, DTBP crosslinked chitosan
sponges were created and evaluated through a vancomycin elution screening study.
Materials and Methods
DTBP and Tris were purchased from Sigma Aldrich (St. Louis, MO) and Fisher
Scientific (Pittsburgh, PA). A 5 mM DTBP solution was prepared by adding 0.03865
grams of DTBP to 25 mL of 0.2 M Tris solution, at a pH of 9, and mixing. A lyophilized
and neutralized 1 % (w/v) chitosan sponge, with 71% DDA, was submerged into the
DTBP solution and allowed to crosslink at ambient temperature for approximately 25
hours. The sponge was then rinsed multiple times with deionized water, until a neutral
pH was reached. The sponges were then placed in the -80°C freezer for one hour and
then lyophilized for 24 hours.
The DTBP crosslinked sponge, with a weight of 0.1739 grams, was submerged
into ten milliliters of a 5 mg/ml vancomycin solution for one minute. Immediately after
vancomycin loading, the sponge was submerged in 20 mL of sterile 1 x PBS and was
incubated at 37°C for the duration of the study. One milliliter aliquots were taken at 1, 2,
25, and 72 hours, with complete PBS refreshment at each time point. The elution
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samples were immediately frozen after acquisition. Fluorescence polarization
immunoassay (TDxFLx) with a vancomycin specific reagent kit was used to quantify the
vancomycin released from the sponge.

Results and Discussion
The 5 mM DTBP crosslinked chitosan sponge was smaller in size, with a 50%
smaller diameter, than the uncrosslinked, genipin crosslinked, and PNIPAM/genipin
crosslinked chitosan sponges and appeared less porous. A photograph of the crosslinked
sponge was taken with a digital camera, as seen in Figure 1. The DTBP crosslinked
sponge absorbed only 0.5 mL of the vancomycin solution, which was 82.0, 90.8, and
91.3% less than average volume of antibiotic solution absorbed by the uncrosslinked,
genipin crosslinked, and PNIPAM/genipin crosslinked chitosan, respectively.

Fig. 1. Photograph of 5 mM DTBP crosslinked chitosan sponge
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The low amount of vancomycin released from the DTBP crosslinked chitosan
sponge can be seen in Figure 2. However, this low elution was expected due to the low
antibiotic uptake. Because of the reduced apparent porosity, vancomycin uptake and
elution, the DTBP crosslinked chitosan sponges did not appear to be effective for a local
drug delivery system and were not studied more extensively. While the DTBP
crosslinked sponge was not absorbent enough to effectively release antibiotics, it might
demonstrate greater potential as a tissue engineering scaffold because of better strength
and handling properties, as compared to the uncrosslinked and genipin crosslinked
chitosan sponges.
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Fig. 2. The vancomycin elution from a DTBP crosslinked chitosan sponge (n = 1)
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APPENIDIX B:
Bioadhesion Testing
Introduction
Bioadhesion is critical in musculoskeletal infection control because the material
needs to be able to stay in place in order to deliver the drugs to the target site. In
previous research on chitosan sponges, some of the sponges studied in an animal study
did not adhere to the local tissues of goats, reducing the effectiveness of the local drug
delivery.60 Measuring the bioadhesive strength of the sponges in vitro could provide a
method of comparison between the uncrosslinked and crosslinked chitosan sponges
before in vivo testing.
Experimental methods of analyzing and measuring bioadhesion vary greatly and
no standard test methods have been developed.92 Thus, it can be difficult to compare data
from different experiments. Various types of mechanical tests have been developed for
testing bioadhesion, both in vivo and in vitro. One research group developed a
customized piece of equipment for bioadhesion tensile testing, where mouse skin was
placed on either side of the hydrogel and bonding strength of the hydrogels was reported
as the maximum detachment force.93 While studying a fucoidan-chitosan hydrogel for
burn healing applications, researchers used a Texture Analyzer and chicken back skin and
calculated the work of adhesion as the area under the curve of a force distance plot.94
Tensile and shear measurements are the most common mechanical tests utilized for
bioadhesion testing.92 In this preliminary study, a standard tensile testing method was
modified for bioadhesive strength measurements of the uncrosslinked and crosslinked
chitosan sponges.
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Materials and Methods
USDA grade boneless beef chuck steak was purchased from a local grocery store,
Kroger, and was allowed to equilibrate to ambient laboratory temperature. The steak was
cut into pieces to fit on a stage fixture, with a 7.62 cm diameter, attached to a Instron
33R, model 4465, Universal Testing Machine (Norwood, MA). The steak was attached
to the stage with Scotch® double sided tape. A washer style disk made of ultra high
molecular weight polyethylene (UHMWPE), with a full diameter, a cut out inner
diameter, and thickness of 7.62, 3.06, 0.635 cm, respectively, was centered and fixed
onto the top of the steak, held in place temporarily with standard office binder clips
(Figure 3). The UHMWPE washer contained one rough side for attachment to the meat,
and one smooth side so as not to interfere with the adhesive strength of the sponges. The
binder clips were removed from the meat and UHMWPE washer approximately one
minute before testing and were replaced between each sponge bioadhesion test. The
UHMWPE washer was clamped onto the steak until the meat was raised just slightly
higher than the disk itself, as seen in Figure 3, so that the sponges would only attach to
the steak. In order to keep the meat from drying, the meat was sprayed with deionized
water, which was allowed to absorb for approximately 5-10 minutes, between
bioadhesion testing of each sponge. A similar fresh piece of chuck steak was cut and
fixed to the testing machine every time a sponge group was changed.
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Fig. 3. Bioadhesion testing preparation by temporarily clamping boneless chuck steak
and a UHMWPE washer with binder clips, in order to keep the two materials in place and
to raise the meat above the washer.

Three replications of uncrosslinked, genipin crosslinked, and PNIPAM/genipin
crosslinked chitosan sponges were submerged in 10 mL of deionized water for 1 minute
and centered and attached to the top stage of the universal testing machine with Scotch®
double sided tape (Figure 4). Using a 500 N load cell automated by Instron Bluehill
software, a compression preload of approximately 15 N was applied to each sponge.
Immediately after applying the preload force, the sponge and the meat were pulled apart
in tension at a rate of 50 mm/min. Data was recorded every 30 milliseconds and was
provided in maximum force (N) values, which was divided by the surface area of the
exposed steak to determine adhesive strength (kPa). All quantitative data are expressed
as mean ± standard deviation (n ≥ 3 for all groups). Statistical analysis of the
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bioadhesion data was conducted using one way ANOVA and Holm-Sidak post hoc
analysis. Analysis was performed using 2007 Microsoft Excel software (Microsoft, Inc,
Redmond, WA) and a p value of < 0.05 was considered statistically significant.

Fig. 4. Bioadhesion testing fixtures with a genipin crosslinked chitosan sponge attached
to the top cylindrical fixture of the universal testing machine

Results and Discussion
The bioadhesive strength in kPa of each type of chitosan sponge is provided in
Figure 5. The maximum force required for the uncrosslinked, genipin crosslinked, and
PNIPAM/genipin crosslinked chitosan sponges to detach was 11.17 ± 3.18, 7.33 ± 1.46,
and 8.44 ± 0.99 N, respectively. There was a significant difference between the
uncrosslinked and genipin crosslinked chitosan sponges (p = 0.001). Crosslinking the
chitosan sponge appears to slightly reduce the bioadhesive strength, not increase the
75

bioadhesion as originally hypothesized. The maximum detachment force of the all three
sponge types are higher than peak detachment force reported for 2 % (w/v) chitosan films
made with either 2 % (w/v) acetic or 1% (w/v) lactic acid, 0.47 ± 0.03 and 0.71 ± 0.02 N,
respectively.95 However, the maximum detachment forces of the uncrosslinked and
crosslinked chitosan sponges found in this study were lower than the average peak
detachment force value, 46.93 N, found for 1% chitosan sponges (85% DDA) made with
2% acetic acid.96 The bioadhesion testing methods used to obtain the maximum
detachment force values in the two previous studies are similar to the modified tensile
test presented here, but the two previous studies utilized a texture analyzer and chicken
pouch tissue or rabbit thigh muscle.95, 96
While in vitro bioadhesion tests provide useful material characterization
properties, the wide variety of testing methods and types of data seen in previous research
makes direct comparisons between studies difficult. However, modified in vitro
bioadhesion tests do provide a faster and easier method of comparison between different
materials, as compared to in vivo studies. Limitations of this modified tensile test for
bioadhesion include 1) the test was conducted with a large load cell and needs to be ran
with a smaller load cell for more accurate results, 2) to better simulate physiological
conditions, the sponges need to be loaded with PBS, instead of deionized water, and 3)
the bioadhesion of the sponges should be tested on different types of tissues.
Additionally, while in vitro bioadhesion tests provide useful material characterization
properties, the most accurate bioadhesion test is an in vivo animal model. In vitro results
can be difficult to translate to in vivo studies and bioadhesion characteristics in vivo,
especially in a musculoskeletal wound, are different from in vitro bioadhesion properties.
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Fig. 5. Adhesive strength (kPa) of uncrosslinked, genipin crosslinked, and PNIPAM/
genipin crosslinked chitosan sponges to USDA grade boneless chuck steak, represented
as mean ± standard deviation with n = 3 for all groups (*, p = 0.001)
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APPENDIX C:
Photographs of Uncrosslinked and Crosslinked Chitosan Sponges
Photographs of the uncrosslinked, genipin crosslinked, and PNIPAM/genipin
crosslinked were acquired with a Kodak Easy Share DX4530 digital camera. Neutralized
uncrosslinked, genipin crosslinked, and PNIPAM/ genipin crosslinked chitosan sponges
can be seen in Figure 6. The genipin crosslinked chitosan sponge exhibits a green color,
due to the crosslinking reaction. The PNIPAM/ genipin crosslinked chitosan sponge
exhibits a slightly bluer color than the genipin crosslinked chitosan sponge.

(A)

(B)

(C)

Fig. 6. Photographs of neutralized (A) uncrosslinked chitosan sponge (B) genipin
crosslinked chitosan sponge and (C) PNIPAM/ genipin crosslinked chitosan sponge
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APPENDIX D:
Water Uptake in the Uncrosslinked and Crosslinked Chitosan Sponges
In addition to antibiotic solution uptake studies, the uptake of deionized water into
the uncrosslinked and crosslinked sponges was investigated to determine if antibiotics are
absorbed differently than water. The same procedure for uptake was followed as outlined
in the materials and methods section of Chapter 3, except 10 mL of deionized water was
used in place of 10 mL of 5 mg/ml antibiotic solution. The volume of water absorbed
into the sponges and the volume of water absorbed, normalized to the weights of the
sponges, is provided in Table 1. Significant differences were seen between the
uncrosslinked and genipin crosslinked sponges (p = 0.0015) and between the
uncrosslinked and PNIPAM/genipin crosslinked sponges (p = 0.0017).

Table 1. Deionized (DI) water uptake in uncrosslinked and crosslinked chitosan sponges
(n = 3 for each group)
DI Water Uptake
DI Water Uptake (mL/ g of
Sponge
(mL)
sponge)
*, †
Uncrosslinked
1.63 ± 0.39
7.86 ± 2.51
*
Genipin crosslinked
4.83 ± 1.27
20.52 ± 5.80
PNIPAM/genipin
crosslinked†
5.35 ± 0.07
29.41 ± 1.00
Data represented as mean ± standard deviation (*, p = 0.0015; †, p = 0.0017)

The volume of water absorbed by the sponge normalized to sponge weight was
lower in the uncrosslinked and genipin crosslinked chitosan sponges than the volume of
antibiotic solution absorbed (see Figure 4 in Chapter 3). However, the PNIPAM/genipin
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crosslinked sponges absorbed more water (mL/g) than antibiotic solution (mL/g). The
introduction of PNIPAM into the genipin crosslinked sponges might make the sponge
more absorbent overall because of the increase of interpenetrating polymer chains, but
could also be causing steric hindrance issues with the antibiotics.
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APPENDIX E:
Degradation of Uncrosslinked Chitosan Sponges Neutralized in 1 M NaOH
The high degradation of the uncrosslinked chitosan sponges reported in Chapter 3,
significantly higher than values previously reported, raised concerns about residual
acidity in the sponges. In order to evaluate the neutralization process and the resulting
degradation, uncrosslinked chitosan sponges were constructed by the same procedure as
noted in Chapter 3 and neutralized in 1 M, instead of 0.2 M, NaOH. The sponges were
submerged in the NaOH solution for approximately two to three minutes, until bubbles
were no longer emerging from the sponges. The sponges were then submerged in
approximately 750 mL of distilled water and stirred constantly on a stir plate. After ten
minutes, the pH of the water was tested using an Accumet basic AB15 pH meter and
electrode and the distilled water was refreshed. The sponges were allowed to stir in the
distilled water for approximately 30 more minutes, the water was refreshed again and the
same procedure was followed two more times. Both the pH of the water and the pH of
the sponges were tested using a pH electrode and pH strips. The sponges were returned
to the -80°C freezer for one hour, and then re-lyophilized for 48 hours.
The sponges were cut into pieces, with three replicates for each time point, and
tested for degradation following the same protocol outlined in Chapter 3. Because the
originally tested uncrosslinked sponges degraded so quickly, degradation samples were
analyzed after 1, 3, 5, 7, and 14 days, instead of after 1, 2, 3, and 6 weeks.
The results from degradation study on the neutral uncrosslinked chitosan sponges
are provided in Figure 7. The percent remaining of the sponges neutralized in 1 M NaOH
is significantly higher than the percent remaining of the sponges neutralized in 0.2 M
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NaOH seen in Chapter 2. After one week in the lysozyme solution, 92.24 ± 0.66% of the
original 1 M NaOH neutralized sponges remained, while only 4.49 ± 2.28% of the 0.2 M
NaOH chitosan sponges remained. However, there were no significant differences
between the degradation times of the 1 M NaOH neutralized sponges (p = 0.99).
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Fig. 7. The degradation of unsterilized and uncrosslinked chitosan sponges, neutralized 1
M NaOH, without antibiotics in 100 µg/ml lysozyme solution represented as mean ±
standard deviation. n = 3 for all groups (p = 0.99)

These degradation results indicate there is a difference in the acidity of the
sponges, when neutralized in different concentrations of NaOH. While sterilization
might also be a factor in the differences in degradation, sterilization should theoretically
result in a decrease in degradation, not an increase, because of the small amount of
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crosslinking induced through the gamma irradiation process. Although direct
comparisons with the crosslinked chitosan sponges cannot be made because of
sterilization differences and a shorter study time, the degradation trend of completely
neutralized uncrosslinked chitosan sponges can be seen through this preliminary study.
For comparison with the crosslinked sponges, another in vitro degradation study should
be conducted with sterilized, 1 M NaOH neutralized, uncrosslinked chitosan sponges for
six weeks.
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